Related Experiment Video
Updated: Jun 28, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.4K
Thyroid dysfunction in nonvalvular atrial fibrillation and clinical outcomes
Zeni Chen1, Huaibin Wan2,3, Tingting Min3
1Department of Cardiology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Endocrine
|April 22, 2024
Summary
Thyroid dysfunction, specifically low triiodothyronine (T3) syndrome, increases risks for patients with nonvalvular atrial fibrillation (NVAF). This condition is linked to higher rates of heart failure, death, and thromboembolism.
Area of Science:
- Cardiology
- Endocrinology
- Internal Medicine
Background:
- Thyroid dysfunction's impact on atrial fibrillation (AF) patients remains understudied.
- Investigating thyroid function in nonvalvular atrial fibrillation (NVAF) patients is crucial for understanding clinical outcomes.
Purpose of the Study:
- To examine the relationship between thyroid dysfunction and thromboembolic risk in NVAF patients.
- To assess the association between thyroid function and clinical composite endpoints in NVAF.
Main Methods:
- Retrospective analysis of 1329 NVAF patients diagnosed between 2016-2020.
- Assessed correlations between thyroid dysfunction, CHA2DS2-VASc scores, and clinical endpoints (death, heart failure, embolism, hemorrhage).
Main Results:
- Low triiodothyronine (T3) syndrome was observed in 6.7% of patients.
- Lower total triiodothyronine (TT3) levels correlated with increased thromboembolism risk (P<0.005).
- Low T3 syndrome independently predicted higher risk of clinical composite endpoint (HR 1.68), heart failure (HR 1.52), and all-cause death (HR 3.34) in adjusted models.
Conclusions:
- Low T3 syndrome is associated with increased risk of heart failure and all-cause death in NVAF patients.
- NVAF patients with low TT3 levels face a higher risk of thromboembolism.
Keywords:
Atrial fibrillationLow T3 syndromeSubclinical thyroid dysfunctionThromboembolismThyroid functionMore Related Videos
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:28Disturbances in Heart Rhythm
945
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
945
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:20Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K